Drugs / UBT38006
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07630233 | Jun → Oct 2026 expected | type 2 diabetes mellitus | The United Bio-Technology (Hengqin) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UBT38006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07630233 ↗ |
| Route | Subcutaneous | “single subcutaneous doses of UBT38006 injection” NCT07630233 ↗ |